Effects of Continuous Vasopressin Infusion in Patients with Septic Shock

Abstract

Spanish

French

BACKGROUND:

Small studies have reported that vasopressin improves hemodynamic instability in patients with septic shock.

OBJECTIVE:

To determine whether vasopressin infusion increases blood pressure, decreases catecholamine vasopressor use, and improves renal function in a large patient population with septic shock when used in a clinical setting.

METHODS:

A retrospective chart audit was conducted of critically ill patients who received vasopressin infusion for septic shock from January 2000 through September 2002. Demographic, hemodynamic, laboratory, vasopressor, and adverse event data were collected. Statistical methods included ANOVA with Tukey's test for post hoc analysis.

RESULTS:

A total of 102 of 353 patients met study criteria. The mean ± SD vasopressin dosage regimen was 0.11 ± 0.17 units/min for 53.8 ± 71.5 hours. Compared with baseline, vasopressin infusion improved mean arterial pressure (MAP) by 15% within one hour (p < 0.05), reduced heart rate by 9% within 4 hours (p < 0.05), and reduced hourly dopamine dosage by 25% within 8 hours (p < 0.05). These effects persisted through 96 hours. Other hemodynamic variables and catecholamine vasopressor usage parameters were not statistically different from baseline. Urine output, serum creatinine, and serum sodium concentrations were not statistically changed from baseline. Adverse events possibly associated with vasopressin infusion included ischemic digits/extremities, myocardial infarction, and hyponatremia.

CONCLUSIONS:

Vasopressin infusion was effective in increasing MAP and reducing heart rate while decreasing the dopamine dosage in patients with septic shock. Comparative studies with catecholamine vasopressors are needed to define the optimal role of vasopressin in septic shock therapy. In the meantime, vasopressin infusion at ≤0.03 units/min should be considered only if response to 1 or 2 catecholamine vasopressors is inadequate or as a method to reduce the dose of these therapies.

Keywords

septic shock vasopressin

Get full access to this article

View all access options for this article.

References

Angus

Linde-Zwirble

Lidicker

Clermont

Carcillo

Pinsky

. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care. Crit Care Med 2001;29:1303–10.

Parillo

JE.

Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471–8.

Vincent

, International Sepsis Forum. Hemodynamic support in septic shock. Intensive Care Med 2001;27(suppl 1):S80–92.

Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999;27:639–60.

Stump

Wallace

Gilberto

Gehret

Lynch

JJ.

Arrhythmogenic potential of positive inotropic agents. Basic Res Cardiol 2000;95:186–98.

Tisdale

Patel

Webb

Borzak

Zarowitz

BJ.

Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother 1995;29:269–81.

Landry

Levin

Gallant

Ashton

Seo

D'Alessandro

Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122–5.

Sharshar

Blanchard

Paillard

Raphael

Gajdos

Annane

Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752–8.

Rozenfeld

Cheng

The role of vasopressin in the treatment of vasodilation in shock states. Ann Pharmacother 2000;34:250–4. DOI 10.1345/aph.19066.

10.

Holmes

Patel

Russell

Walley

KR.

Physiology of vasopressin relevant to management of shock. Chest 2001;120:989–1002.

11.

Patel

Chittock

Russell

Walley

KR.

Beneficial effects of short-term vasopressin infusion during severe shock. Anesthesiology 2002;96:576–82.

12.

Malay

Ashton

Landry

Townsend

RN.

Low-dose vasopressin in the treatment of vasodilatory shock. J Trauma 1999;47:699–705.

13.

Landry

Levin

Gallant

Seo

D'Alessandro

Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279–82.

14.

Garcia

Franco

Aguirre

Martinez

Haemodynamic effects of early vasopressin infusion during septic shock (abstract). Crit Care Med 2002;30:A107.

15.

Tsuneyoshi

Yamada

Kakihana

Nakamura

Nakano

Boyle

WA.

Hemodynamic and metabolic effects of low-dose vasopressin infusion in vasodilatory shock. Crit Care Med 2001;29:487–93.

16.

Bracco

Revelly

JP.

Systemic and splanchnic haemodynamic effects of vasopressin administration in vasodilatory shock (abstract). Intensive Care Med 2001;27:S138.

17.

Dunser

Mayr

Ulmer

Knotzer

Sumann

Pajk

Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003;107:2313–9.

18.

Holmes

Walley

Chittock

Lehman

Russell

JA.

The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001;27:1416–21.

19.

Garcia

Sandoval

Aguirre

Elizalde

Franco

Martinez

Vasopressin infusion improves the hemodynamics in patients with septic shock (abstract). Crit Care Med 2001;29:A90.

20.

Mann

Beilman

Song

Farrell

Hasinoff

Lohr

BC.

Outcome of vasopressin treatment in vasodilatory septic shock (abstract). Crit Care Med 2000;28:A184.

21.

Malevanov

Klapholz

Dinan

Talavera

Vasopressin therapy in patients with refractory shock (abstract). www.abstracts-on-line.com/abstracts/ATS/windowview.asp?abs=ATS2L_202694 (accessed 2002 Jun 11).

22.

Anwar

Adams

RG.

Effect of vasopressin on hemodynamic profile in patients with septic shock (abstract). www.abstracts-on-line.com/abstracts/ATS/windowview.asp?abs=ATS2L_201063 (accessed 2002 Jun 11).

23.

Gold

Hehn

Landry

DL.

Vasopressin for the treatment of septic shock (abstract). Am J Respir Crit Care Med 1998;157:A116.

24.

Dunser

Mayr

Ulmer

Ritsch

Knotzer

Pajk

The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg 2001;93:7–13.

25.

Dabbagh

Ayoub

Alshirwai

Arabi

Al Shimemeri

Use of vasopressin infusion as salvage therapy in septic patients on high dose catecholamines (abstract). Chest 2003;124:S224.

26.

Klinzing

Simon

Reinhart

Bredle

Meier-Hellmann

Highdose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003;31:2646–50.

27.

Bone

Balk

Cerra

Dellinger

Fein

Knaus

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644–55.

28.

Bernard

Vincent

J-L

Laterre

P-F

LaRosa

Dhainaut

J-F

Lopez-Rodriguez

Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.

29.

Annane

Sebille

Charpentier

Bollaert

Francois

Korach

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862–71.

30.

Dunser

Mayr

Tur

Pajk

Barbara

Knotzer

Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med 2003;31:1394–8.

31.

Russell

JA.

Vasopressin in septic shock: Clinical equipoise mandates a time for restraint. Crit Care Med 2003;31:2707–9.

32.

Dellinger

RP.

Cardiovascular management of septic shock. Crit Care Med 2003;31:946–55.

33.

Dellinger

Carlet

Masur

Gerlach

Calandra

Cohen

Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858–73.